Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low SARS-CoV-2 seroprevalence in a cohort of Brazilian sickle cell disease patients: Possible effects of emphasis on social isolation for a population initially considered to be at very high risk.
Trafane LF, da Costa VA, da Silva Santos Duarte A, Zangirolami AB, Proenca-Modena JL, de Melo Campos P, de Souza Medina S, Saad STO, Addas-Carvalho M, Benites BD. Trafane LF, et al. Among authors: de souza medina s. EJHaem. 2021 Jun 17;2(3):478-482. doi: 10.1002/jha2.254. eCollection 2021 Aug. EJHaem. 2021. PMID: 34518833 Free PMC article.
Montreal cognitive assessment in Brazilian adults with sickle cell disease: The burdens of poor sociocultural background.
Junqueira Fleury Silva P, Martins Silva C, Machado de Campos B, de Melo Campos P, de Souza Medina S, Lamonica A, Coimbra Trindade JV, Cendes F, Costa FF, Olalla Saad ST, Deltreggia Benites B. Junqueira Fleury Silva P, et al. Among authors: de souza medina s. EJHaem. 2024 Mar 28;5(2):308-315. doi: 10.1002/jha2.875. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633117 Free PMC article.
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR. Idowu M, et al. Among authors: de souza medina s. Lancet Haematol. 2025 Jan;12(1):e35-e44. doi: 10.1016/S2352-3026(24)00319-3. Epub 2024 Dec 4. Lancet Haematol. 2025. PMID: 39644907 Clinical Trial.
Radioligand Therapy in Lymphoma: Past, Present, and Future.
Almeida LS, Delgado Bolton RC, Heringer VC, de Souza Medina S, Etchebehere E. Almeida LS, et al. Among authors: de souza medina s. PET Clin. 2024 Oct;19(4):475-494. doi: 10.1016/j.cpet.2024.05.003. Epub 2024 Jul 4. PET Clin. 2024. PMID: 38969564